阿维莫泮与腹部手术后结局的系统综述
该系统综述检索主要数据库,纳入9项随机对照试验和35项非随机研究,评估阿维莫泮对腹部手术后结局的影响。低至中等确定性证据支持阿维莫泮缩短开腹肠切除和开腹根治性膀胱切除术后的住院时间并改善胃肠功能恢复;对微创手术和当代加速康复路径患者的获益尚不确定。
要点
- 阿维莫泮可缩短开腹肠切除和开腹根治性膀胱切除术后的住院时间并改善胃肠恢复。
- 对微创手术患者,支持阿维莫泮的证据确定性极低。
- 在传统护理与加速康复路径下效果相似,但路径要素在各研究间存在差异。
核心结论
- 证据支持阿维莫泮改善开腹肠切除和开腹根治性膀胱切除术后的结局。
- 对微创手术及当代加速康复路径下患者的获益仍不确定。
研究设计与样本
- 系统综述,检索Medline、Embase、Biosis、Cochrane、Web of Science和Scopus。
- 纳入比较阿维莫泮与对照的随机对照试验和非随机研究。
- 共纳入9项随机对照试验和35项非随机研究。
- 因报告异质性和偏倚风险阻碍荟萃分析,结果采用描述性评价。
主要发现
- 低至中等确定性证据支持阿维莫泮减少开腹肠切除和开腹根治性膀胱切除术后的住院时间并改善胃肠功能恢复。
- 有限证据支持阿维莫泮用于FDA标签未列出的手术(如全腹子宫切除术和腹膜后淋巴结清扫术)。
- 在传统护理和加速康复路径设置中观察到相似效果,但加速康复路径要素在各研究间存在差异。
- 支持阿维莫泮用于微创手术患者的证据确定性极低。
临床怎么用
- 可考虑将阿维莫泮用于开腹肠切除和开腹根治性膀胱切除术患者以改善术后结局。
- 对微创手术患者使用阿维莫泮应谨慎,因证据确定性极低。
- 在加速康复路径中使用阿维莫泮需考虑路径要素的差异。
局限性
- 报告异质性和偏倚风险阻碍了荟萃分析。
- 加速康复路径要素在各研究间存在差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Alvimopan is a Food and Drug Administration-approved treatment to accelerate gastrointestinal recovery after abdominal surgery; however, benefits may vary across different procedures and contexts of care. The purpose of this study is to summarize the evidence regarding the effect of alvimopan on postoperative outcomes after abdominal surgery. METHODS: Major databases (Medline, Embase, Biosis, Cochrane, Web of Science, and Scopus) were searched for randomized controlled trials and nonrandomized studies comparing alvimopan versus control. Risk of bias was assessed using Cochrane's risk of bias tool 2.0 (for randomized controlled trials) and Risk of Bias in Nonrandomized Studies-of Intervention tool (for nonrandomized studies). Results were appraised descriptively as heterogeneity in reporting and risk of bias hindered meta-analysis. Quality of evidence across different surgical procedures and contexts of care (ie, open versus minimally invasive surgery, traditional care versus enhanced recovery pathway) was evaluated using Grading of Recommendations Assessment, Development, and Evaluation. RESULTS: Nine randomized controlled trials and 35 nonrandomized studies were identified. Evidence of low to moderate certainty supports that alvimopan reduces length of stay and improves gastrointestinal recovery after open bowel resection and open radical cystectomy. Limited evidence supports alvimopan for surgeries not listed in Food and Drug Administration labels (ie, total abdominal hysterectomy and retroperitoneal lymph node dissection). Similar effects were observed in traditional and enhanced recovery pathway settings, but enhanced recovery pathway elements varied across studies. There is very low certainty of evidence supporting alvimopan for patients undergoing minimally invasive surgery. CONCLUSION: Evidence supports that alvimopan improves outcomes after open bowel resection and open radical cystectomy. Benefits for patients undergoing minimally invasive surgery and treated in contemporary enhanced recovery pathway settings remain uncertain. These findings contribute important new knowledge to inform evidence-based alvimopan prescribing.
引用
- Alhashemi M, Hamad R, El-Kefraoui C, et al. The association of alvimopan treatment with postoperative outcomes after abdominal surgery: A systematic review across different surgical procedures and contexts of perioperative care. Surgery. 2020. PMID: 33380353. doi:10.1016/j.surg.2020.11.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。